Sharemaestro company-news research for Lantern Pharma Inc (LTRN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest LTRN news and sentiment

Lantern Pharma Inc

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score50Neutral is 50
Early balanced news score 17/100 evidence confidence 100% direct company focus 18 current stories across 8 publishers
Latest weekly closeUSD 1.90week of 4 Sep 2026
Main news subjectEarnings85/100 share of current news
News data statusPartial22 duplicate stories removed

Current company news

Early balanced news score

18 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone48/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Lantern Pharma Earnings Call: AI Spinout, Trial Momentum TipRanks · 25 Aug 2026 00:27

What supports the score

Direct evidence

18 current stories are mapped specifically to LTRN.

Source breadth

The score uses 8 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.069.

Confidence

Confidence is 17/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
17/100
Confidencethin evidence
100%/100
Company news18 company stories
81/100
Story agreement19/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
12 Aug: 1 stories14 Aug: 9 stories15 Aug: 1 stories16 Aug: 1 stories17 Aug: 1 stories18 Aug: 2 stories21 Aug: 1 stories22 Aug: 1 stories25 Aug: 1 stories 12 Aug: tone 68, 1 stories14 Aug: tone 39, 9 stories15 Aug: tone 75, 1 stories16 Aug: tone 50, 1 stories17 Aug: tone 59, 1 stories18 Aug: tone 44, 2 stories21 Aug: tone 50, 1 stories22 Aug: tone 50, 1 stories25 Aug: tone 50, 1 stories 95505
11 Aug26 Aug09 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence1
0.069 after freshness weighting
Source breadth100
8 independent publishers
Company relevance100
share tied directly to this company
Freshness3
recency-weighted evidence
Agreement81
how closely stories agree
Publisher mix73
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks11 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar 2026: close 2.39, indexed 100.020 Mar 2026: close 2.13, indexed 89.127 Mar 2026: close 1.12, indexed 46.903 Apr 2026: close 1.62, indexed 67.810 Apr 2026: close 1.97, indexed 82.417 Apr 2026: close 2.49, indexed 104.224 Apr 2026: close 2.46, indexed 102.901 May 2026: close 2.12, indexed 88.708 May 2026: close 2.1, indexed 87.915 May 2026: close 3.14, indexed 131.422 May 2026: close 3.5, indexed 146.429 May 2026: close 3.59, indexed 150.205 Jun 2026: close 3.59, indexed 150.212 Jun 2026: close 3.88, indexed 162.319 Jun 2026: close 3.79, indexed 158.626 Jun 2026: close 3.86, indexed 161.503 Jul 2026: close 3.97, indexed 166.110 Jul 2026: close 3.6, indexed 150.617 Jul 2026: close 2.87, indexed 120.124 Jul 2026: close 2.75, indexed 115.131 Jul 2026: close 2.63, indexed 110.007 Aug 2026: close 2.86, indexed 119.714 Aug 2026: close 2.65, indexed 110.921 Aug 2026: close 2.34, indexed 97.928 Aug 2026: close 2.07, indexed 86.604 Sep 2026: close 1.905, indexed 79.7 26 Jun 2026: news score 50, close 3.86, 2 stories5003 Jul 2026: news score 50, close 3.97, 2 stories10 Jul 2026: news score 50, close 3.6, 4 stories5017 Jul 2026: news score 50, close 2.87, 7 stories24 Jul 2026: news score 50, close 2.75, 10 stories5031 Jul 2026: news score 50, close 2.63, 18 stories07 Aug 2026: news score 49, close 2.86, 29 stories4914 Aug 2026: news score 46, close 2.65, 38 stories21 Aug 2026: news score 49, close 2.34, 42 stories4928 Aug 2026: news score 50, close 2.07, 31 stories04 Sep 2026: news score 50, close 1.905, 23 stories50 Price index 180.4 106.5 32.6 News score 100 50 0
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
26-week price-20.3%latest close 1.90
News score change+0first to latest comparable week
One-week response-8.0%Price reacting lower
Fair-value position-51.1%Below fair value
WeekNews scoreCloseWeekly move
04 Sep 202650USD 1.905-8.0%
28 Aug 202650USD 2.07-11.5%
21 Aug 202649USD 2.34-11.7%
14 Aug 202646USD 2.65-7.3%
07 Aug 202649USD 2.86+8.7%
31 Jul 202650USD 2.63-4.4%
24 Jul 202650USD 2.75-4.2%
17 Jul 202650USD 2.87-20.3%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings4913 stories · 72%
Market update473 stories · 17%
Balance sheet502 stories · 11%

Source mix

Where the evidence comes from

73/100 independence
vinanet.vn544 stories · 22%
GuruFocus383 stories · 17%
Investing.com371 stories · 6%
FinancialContent391 stories · 6%
seekingalpha.com601 stories · 6%
Seeking Alpha591 stories · 6%
AlphaStreet431 stories · 6%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences7Earnings7Technology5Finance5Financial Markets3Ratings1Financing1Fda Approval1Clinical Trials1AI1

Earlier readings

How the score has changed

27 comparable readings · 78 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range46–5250 is the neutral baseline
Evidence depth18stories at latest stored reading · +17
Confidence16/100Provisional · +16
22 Jun50 neutral09 Sep 00:30
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
09 Sep 00:3050+116/100 (-10)18 (-17)Provisional
25 Aug 23:5949+026/100 (-5)35 (-6)Provisional
22 Aug 23:5949+031/100 (-2)41 (-1)Provisional
21 Aug 23:5949+033/100 (-9)42 (+1)Provisional
18 Aug 23:5949-142/100 (+4)41 (+2)Measured
17 Aug 23:5950+138/100 (0)39 (+1)Measured
16 Aug 23:5949+038/100 (-3)38 (0)Measured
15 Aug 23:5949+341/100 (-1)38 (0)Measured

Source headlines

The news behind the score

Showing 1-18 of 18

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
TipRanksDirect company coverageScored from headline

Lantern Pharma Earnings Call: AI Spinout, Trial Momentum

Published
25 Aug 2026 00:27
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.0d old
Duplicates
1 consolidated
#2—Not directional
The Globe and MailDirect company coverageStored article

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma (LTRN) discussed its Q2 2026 earnings, highlighting a 25% reduction in operating expenses year-over-year while advancing multiple clinical programs. A significant development was the establishment of Open Medicine AI (OMAI) as a separate company to commercialize its AI platform, with Lantern Pharma retaining full ownership and access. The call also detailed promising clinical data for LP-300 in non-small cell lung cancer and LP-184 in bladder and triple-negative breast cancer, along with strategic financial priorities including securing additional funding.

EarningsFinanceLife SciencesTechnology
Published
22 Aug 2026 09:41
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.6d old
Duplicates
2 consolidated
#3—Not directional
SahmDirect company coverageStored article

Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Lantern Pharma (NASDAQ:LTRN) faces concerns regarding its cash burn rate, with a cash runway of only about six months based on its US$14 million annual burn and US$7.4 million cash reserves as of June 2026. While the company has reduced its cash burn by 21% over the past year, its ability to raise additional capital is questionable given that its burn represents 48% of its US$30 million market capitalization, suggesting potential for a highly dilutive capital raise. This short runway and significant relative cash burn indicate a risky financial situation for the early-stage business.

EarningsFinanceLife Sciences
Published
21 Aug 2026 09:41
News subject
Balance sheet
Why this score
Cash generation improved, Dilution risk
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 18.6d old
Duplicates
1 consolidated
#659Tone
Seeking AlphaDirect company coverageStored article

Lantern Pharma Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2026-08-17

This article provides details on Lantern Pharma Inc.'s Q2 2026 earnings call presentation, including the reported EPS of -$0.28, which beat estimates by $0.10, and revenue of $0.00, also beating estimates. It highlights that the company published a slide deck in conjunction with the call. The content is from Seeking Alpha's transcripts team.

EarningsFinanceLife SciencesTechnology
Published
17 Aug 2026 23:12
News subject
Earnings
Why this score
Beat expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
13% of the score · 22.1d old
Duplicates
1 consolidated
#7—Not directional
GuruFocusDirect company coverageScored from headline

Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark

Published
16 Aug 2026 14:08
News subject
Balance sheet
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 23.4d old
Duplicates
1 consolidated
#943Tone
AlphaStreetDirect company coverageScored from headline

Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share

Published
14 Aug 2026 19:50
News subject
Market update
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 28/100
30-day weight
<0.1% of the score · 25.2d old
Duplicates
1 consolidated
#10—Not directional
GuruFocusDirect company coverageScored from headline

Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges

Published
14 Aug 2026 18:14
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 25.3d old
Duplicates
1 consolidated
#1160Tone
seekingalpha.comDirect company coverageStored article

Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031

Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level,” said (President, CEO & Director Panna Sharma), calling it “the most consequential structural decision we've made since starting Lantern.” * On LP-300 in never-smokers NSCLC after TKI, (President, CEO & Director Sharma) highlighted a subgroup signal: “Among L858R patients who completed 6 cycles, median progression-free survival reached 8.9 months,” whi

AIClinical TrialsEarningsFda ApprovalFinancingRatings
Published
14 Aug 2026 16:48
News subject
Earnings
Why this score
Business expansion
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 37/100
30-day weight
7.4% of the score · 25.3d old
Duplicates
1 consolidated
#1237Tone
Investing.comDirect company coverageStored article

Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips

Lantern Pharma reported a wider-than-expected Q2 2026 net loss of $0.57 per share, primarily due to $3.6 million in non-cash warrant expenses, despite a 25% reduction in operating expenses and significant advancements in its clinical programs. The company also announced the establishment of Open-Medicine AI as a separate entity, aiming to independently raise capital and potentially become a separately listed company, while Lantern retains full access to its AI platform for drug development. The stock slipped 3.8% in premarket trading following the report, reflecting investor caution despite operational improvements and positive long-term analyst outlooks.

EarningsFinancial MarketsLife SciencesTechnology
Published
14 Aug 2026 14:11
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 40/100
30-day weight
9.6% of the score · 25.4d old
Duplicates
1 consolidated
#14—Not directional
Investing.com NigeriaDirect company coverageStored article

Form 8K Lantern Pharma Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Lantern Pharma Inc. on August 14th. It is a brief announcement indicating a regulatory filing, without providing further details about the content of the 8K. The article is from Investing.com and is dated August 14, 2026.

Financial MarketsLife Sciences
Published
14 Aug 2026 12:58
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 25.5d old
Duplicates
1 consolidated
#1543Tone
TradingViewDirect company coverageStored article

Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary

Lantern Pharma Inc. reported a consolidated net loss of $(7.07M) and an EPS of $(0.57) for Q2 2026, marking a significant increase in losses compared to the previous year, with no revenue reported. Despite the financial losses, the company continued to advance its clinical pipeline, including three clinical-stage candidates and AI commercialization efforts. Research and development spending decreased, while general and administrative investments rose.

EarningsFinanceLife SciencesTechnology
Published
14 Aug 2026 11:11
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 32/100
30-day weight
5.9% of the score · 25.6d old
Duplicates
1 consolidated
#16—Not directional
MarketBeatDirect company coverageScored from headline

Lantern Pharma (LTRN) Earnings Date and Reports 2026 $LTRN

Published
14 Aug 2026 07:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 25.7d old
Duplicates
1 consolidated
#1739Tone
FinancialContentDirect company coverageStored article

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma announced its second-quarter 2026 financial results and provided a business update, highlighted by the establishment of Open Medicine AI (OMAI) as a separate company with commercial licensing agreements. The company also reported deepening progression-free survival benefits for LP-300 in EGFR Exon 21 L858R lung cancer and EMA clearance for LP-184 in biomarker-selected bladder cancer. Financial results indicated a 25% decrease in loss from operations year-over-year, while net loss increased due to warrant accounting.

EarningsFinanceFinancial MarketsLife SciencesTechnology
Published
14 Aug 2026 07:30
News subject
Earnings
Why this score
Deteriorating financial comparison
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 38/100
30-day weight
7.5% of the score · 25.7d old
Duplicates
3 consolidated

Earlier company news

LTRN news archive

35 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 35 older LTRN headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

3 not scored

A news provider linked these stories to LTRN, but the headline and available text are not mainly about Lantern Pharma Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of LTRN sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context